STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma

Oncogene

Volumn 32, Issue 45, 2013, Pages 5283-5291

  Bisikirska, B C ^a   Adam, S J ^b   Alvarez, M J ^a   Rajbhandari, P ^a   Cox, R ^a,c   Lefebvre, C ^a   Wang, K ^a,d   Rieckhof, G E ^a   Felsher, D W ^b   Califano, A ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Riverdale Country School   (United States)

^d PFIZER INC   (United States)

Author keywords

MYC post translational modifications; protein turnover; protein protein interaction; STK38; transcriptional activity

Indexed keywords

B LYMPHOCYTE RECEPTOR; MYC PROTEIN; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE 38; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CARCINOGENESIS; CELL SURVIVAL; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CARCINOGENESIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HELA CELLS; HETEROGRAFTS; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, ANTIGEN, B-CELL; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84887470070     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.543     Document Type: Article

References (52)

1. Hergovich A, Schmitz D, Hemmings BA. The human tumour suppressor LATS1 is activated by human MOB1 at the membrane. Biochem Biophys Res Commun 2006; 345: 50-58.
2. Wang K, Alvarez MJ, Bisikirska BC, Linding R, Basso K, Dalla Favera R et al. Dissecting the interface between signaling and transcriptional regulation in human B cells. Pacific Symposium on Biocomputing 2009; 264-275.
3. Wang K, Saito M, Bisikirska BC, Alvarez MJ, Lim WK, Rajbhandari P et al. Genomewide identification of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol 2009; 27: 829-839.
4. Zeller KI, Jegga AG, Aronow BJ, ODonnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 2003; 4: R69.
5. Millward T, Cron P, Hemmings BA. Molecular cloning and characterization of a conserved nuclear serine(threonine) protein kinase. Proc Natl Acad Sci USA 1995; 92(11): 5022-5026.
6. Hergovich A, Lamla S, Nigg EA, Hemmings BA. Centrosome-associated NDR kinase regulates centrosome duplication. Mol Cell 2007; 25: 625-634.
7. Enomoto A, Kido N, Ito M, Morita A, Matsumoto Y, Takamatsu N et al. Negative regulation of MEKK1/2 signaling by serine-threonine kinase 38 (STK38). Oncogene 2008; 27: 1930-1938.
8. Tamaskovic R, Bichsel SJ, Rogniaux H, Stegert MR, Hemmings BA. Mechanism of Ca2-mediated regulation of NDR protein kinase through autophosphorylation and phosphorylation by an upstream kinase. J Biol Chem 2003; 278: 6710-6718.
9. Bhattacharya S, Large E, Heizmann CW, Hemmings B, Chazin WJ. Structure of the Ca2/S100B/NDR kinase peptide complex: insights into S100 target specificity and activation of the kinase. Biochemistry 2003; 42: 14416-14426.
10. Devroe E, Erdjument-Bromage H, Tempst P, Silver PA. Human Mob proteins regulate the NDR1 and NDR2 serine-threonine kinases. J Biol Chem 2004; 279: 24444-24451.
11. Millward TA, Hess D, Hemmings BA. Ndr protein kinase is regulated by phosphorylation on two conserved sequence motifs. J Biol Chem 1999; 274: 33847-33850.
12. Marcu KB, Bossone SA, Patel AJ. Myc function and regulation. Annu Rev Biochem 1992; 61: 809-860.
13. Bouchard C, Staller P, Eilers M. Control of cell proliferation by myc. Trends Cell Biol 1998; 8: 202-206.
14. Felsher DW. Reversibility of oncogene-induced cancer. Curr Opin Genet Dev 2004; 14: 37-42.
15. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer.. Science 2002; 297: 63-64.
16. Tran PT, Bendapudi PK, Lin HJ, Choi P, Koh S, Chen J et al. Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med 2011; 3: 103ra99.
17. Felsher DW. Oncogenes as therapeutic targets. Semin Cancer Biol 2004; 14: 1.
18. Vichalkovski A, Gresko E, Cornils H, Hergovich A, Schmitz D, Hemmings BA. NDR kinase is activated by RASSF1A/MST1 in response to Fas receptor stimulation and promotes apoptosis. Curr Biol 2008; 18: 1889-1895.
19. Kaptein JS, Lin CK, Wang CL, Nguyen TT, Kalunta CI, Park E et al. Anti-IgMmediated regulation of c-myc and its possible relationship to apoptosis. J Biol Chem 1996; 271: 18875-18884.
20. Cornils H, Kohler RS, Hergovich A, Hemmings BA. Human NDR kinases control G(1)/S cell cycle transition by directly regulating p21 stability. Mol Cell Biol 2011; 31: 1382-1395.
21. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J et al. Direct activation of tert transcription by c-MYC. Nat Genet 1999; 21: 220-224.
22. Bonnefoy-Berard N, Genestier L, Flacher M, Rouault JP, Lizard G, Mutin M et al. Apoptosis induced by polyclonal antilymphocyte globulins in human B-cell lines. Blood 1994; 83: 1051-1059.
23. Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci Usa 2007; 104: 13028-13033.
24. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4: 199-207.
25. Bansal M, Califano A. Genome-wide dissection of posttranscriptional and posttranslational interactions. Methods Mol Biol 2012; 786: 131-149.
26. Adeyinka A, Emberley E, Niu Y, Snell L, Murphy LC, Sowter H et al. Analysis of gene expression in ductal carcinoma in situ of the breast. Clin Cancer Res 2002; 8: 3788-3795.
27. Millward TA, Heizmann CW, Schafer BW, Hemmings BA. Calcium regulation of Ndr protein kinase mediated by S100 calcium-binding proteins. EMBO J 1998; 17: 5913-5922.
28. Cui DX, Zhang L, Yan XJ, Zhang LX, Xu JR, Guo YH et al. A microarray-based gastric carcinoma prewarning system. World J Gastroenterol 2005; 11: 1273-1282.
29. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet 2005; 37: 382-390.
30. Hann SR. Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. Semin Cancer Biol 2006; 16: 288-302.
31. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H. Sequencespecific DNA binding by the c-Myc protein. Science 1990; 250: 1149-1151.
32. Sakamuro D, Prendergast GC. New Myc-interacting proteins: a second Myc network emerges. Oncogene 1999; 18: 2942-2954.
33. Herbst A, Hemann MT, Tworkowski KA, Salghetti SE, Lowe SW, Tansey WP. A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO R 2005; 6: 177-183.
34. Herbst A, Salghetti SE, Kim SY, Tansey WP. Multiple cell-type-specific elements regulate Myc protein stability. Oncogene 2004; 23: 3863-3871.
35. Kato GJ, Barrett J, Villa-Garcia M, Dang CV. An amino-terminal c-myc domain required for neoplastic transformation activates transcription. Mol Cell Biol 1990; 10: 5914-5920.
36. Arnold HK, Zhang X, Daniel CJ, Tibbitts D, Escamilla-Powers J, Farrell A et al. The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. EMBO J 2009; 28: 500-512.
37. Mooney LM, Whitmarsh AJ. Docking interactions in the c-Jun N-terminal kinase pathway. J Biol Chem 2004; 279: 11843-11852.
38. Molinari E, Gilman M, Natesan S. Proteasome-mediated degradation of transcriptional activators correlates with activation domain potency in vivo. EMBO J 1999; 18: 6439-6447.
39. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates Myc protein stability and activity. Mol Cell 2003; 11: 1177-1188.
40. Babu MM, van der Lee R, de Groot NS, Gsponer J. Intrinsically disordered proteins: regulation and disease. Curr Opin Struct Biol 2011; 21: 432-440.
41. Nair SK, Burley SK. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 2003; 112: 193-205.
42. Follis AV, Hammoudeh DI, Wang H, Prochownik EV, Metallo SJ. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol 2008; 15: 1149-1155.
43. Ward JJ, Sodhi JS, McGuffin LJ, Buxton BF, Jones DT. Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J Mol Biol 2004; 337: 635-645.
44. Tsvetkov P, Reuven N, Prives C, Shaul Y. Susceptibility of p53 unstructured N terminus to 20 S proteasomal degradation programs the stress response. J Biol Chem 2009; 284: 26234-26242.
45. Tsvetkov P, Reuven N, Shaul Y. The nanny model for IDPs. Nat Chem Biol 2009; 5: 778-781.
46. Engelberg D. Stress-activated protein kinases-tumor suppressors or tumor initiators? Semin Cancer Biol 2004; 14: 271-282.
47. Cornils H, Kohler RS, Hergovich A, Hemmings BA. Downstream of human NDR kinases: impacting on c-myc and p21 protein stability to control cell cycle progression. Cell Cycle 2011; 10: 1897-1904.
48. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002; 297: 102-104.
49. Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 2003; 101: 2797-2803.
50. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M et al. Nontranscriptional control of DNA replication by c-Myc. Nature 2007; 448: 445-451.
51. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. ProcNatl Acad SciUSA 2005; 102(43): 15545-15550.
52. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25-29.